These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25758545)

  • 1. VEGF inhibitors for AMD and diabetic macular edema.
    Med Lett Drugs Ther; 2015 Mar; 57(1464):41-2. PubMed ID: 25758545
    [No Abstract]   [Full Text] [Related]  

  • 2. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-VEGF: one drug for different conditions?].
    Cohen SY; Massin P; Souied E
    J Fr Ophtalmol; 2013 Jan; 36(1):2-4. PubMed ID: 23290491
    [No Abstract]   [Full Text] [Related]  

  • 4. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
    Antoszyk AN; Tarnowski KW; Basu K; Ehrlich JS; Haskova Z
    Ophthalmol Retina; 2020 Oct; 4(10):1034-1036. PubMed ID: 32512056
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-VEGF therapeutic approaches for diabetic macular edema.
    Khurana RN; Do DV; Nguyen QD
    Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
    [No Abstract]   [Full Text] [Related]  

  • 6. Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents.
    Terauchi G; Shinoda K; Sakai H; Kawashima M; Matsumoto CS; Mizota A; Miyake Y
    BMC Ophthalmol; 2019 Jun; 19(1):129. PubMed ID: 31208350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
    Payne JF; Clark WL; Bruce BB; Wykoff CC; Brown DM; Menke BM; Iverson SM; Allen KF; Boyer DS;
    Ophthalmology; 2018 Aug; 125(8):1304-1306. PubMed ID: 29729809
    [No Abstract]   [Full Text] [Related]  

  • 8. Ranibizumab Alters Levels of Intraocular Soluble Cytokine Receptors in Patients with Diabetic Macular Edema.
    Coughlin BA; Guha-Niyogi P; Sikorskii A; Glazer LC; Mohr S
    Curr Eye Res; 2020 Apr; 45(4):509-520. PubMed ID: 31488015
    [No Abstract]   [Full Text] [Related]  

  • 9. Reversal of Retinal Vascular Leakage and Arrest of Progressive Retinal Nonperfusion With Monthly Anti-Vascular Endothelial Growth Factor Therapy for Proliferative Diabetic Retinopathy.
    Gupta MP; Kiss S; Chan RVP
    Retina; 2018 Sep; 38(9):e74-e75. PubMed ID: 30005003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravitreal ranibizumab injection on aqueous humour cytokine levels in patients with diabetic macular oedema.
    Shiraya T; Kato S; Araki F; Ueta T
    Acta Ophthalmol; 2017 Jun; 95(4):e340-e341. PubMed ID: 27545866
    [No Abstract]   [Full Text] [Related]  

  • 11. Nurse-administered intravitreal injections: a systematic review.
    Li E; Greenberg PB; Krzystolik MG
    Graefes Arch Clin Exp Ophthalmol; 2015 Sep; 253(9):1619-21. PubMed ID: 25588804
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
    Behar-Cohen F; Dernigoghossian M; Andrieu-Soler C; Levy R; Cohen R; Zhao M
    Drug Discov Today; 2019 Aug; 24(8):1436-1439. PubMed ID: 31173913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial.
    Călugăru D; Călugăru M
    Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):160. PubMed ID: 29554381
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergency department visits after intravitreal bevacizumab and ranibizumab injections in diabetic patients.
    Johnson D; Jagan L; Kurji A; Jumaa K; Sharma S
    Can J Ophthalmol; 2014 Dec; 49(6):e146-8. PubMed ID: 25433751
    [No Abstract]   [Full Text] [Related]  

  • 15. LESS IS MORE: Reducing Injections and Optimizing Vision With Anti-VEGF Therapy for nAMD, DR, and DME.
    Retina; 2024 May; 44(5S):S1-S16. PubMed ID: 38739858
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
    Nariani A; Williams B; Hariprasad SM
    Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab.
    Willerslev A; Munch IC; Larsen M
    Acta Ophthalmol; 2012 Aug; 90(5):e407-9. PubMed ID: 22268957
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab.
    Funk M; Schmidinger G; Maar N; Bolz M; Benesch T; Zlabinger GJ; Schmidt-Erfurth UM
    Retina; 2010 Oct; 30(9):1412-9. PubMed ID: 20711086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015.
    Hollingworth W; Jones T; Reeves BC; Peto T
    BMJ Open; 2017 Oct; 7(10):e018289. PubMed ID: 29061629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring ocular drug therapy by analysis of aqueous samples.
    Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
    Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.